In a monumental shift toward cosmetic transparency, Health Canada has officially implemented Phase 2 of its fragrance allergen disclosure mandate as of August 1, 2026, requiring beauty brands to list expanded allergen information on product labels.

This regulatory update, enacted through amendment SOR/2024-63, represents Canada's alignment with European Union standards and fundamentally changes how fragrance ingredients must be disclosed to protect consumers with sensitivities.

The New Disclosure Requirements

Under Phase 2, which applies to all new products entering the Canadian market, manufacturers must now disclose an expanded list of 81+ fragrance allergens individually in the ingredient list, rather than grouping them under generic terms like "parfum" or "fragrance."

The thresholds for mandatory disclosure are stringent: fragrance allergens must be listed if they exceed 0.01% in rinse-off products (such as shampoos and soaps) or 0.001% in leave-on products (including lotions and perfumes).

Enhanced Consumer Protection

This protective measure aims to empower individuals with known allergies to identify and avoid specific triggers, significantly reducing the incidence of allergic contact dermatitis across the Canadian population.

For decades, the term "Parfum" served as a protective umbrella for proprietary aromatic blends, shielding trade secrets but leaving consumers with sensitivities uninformed. Health Canada's mandate fundamentally changes this dynamic, prioritizing public health over industry confidentiality.

Implementation Timeline and Compliance

The phased rollout began with Phase 1 on April 12, 2026, requiring disclosure of an initial 24 fragrance allergens. Phase 2, effective August 1, 2026, expands this to 81+ allergens for new products only.

Phase 3, scheduled for August 1, 2028, will require full compliance for the expanded list across all products on the market, giving manufacturers a 12-month grace period to update existing inventory.

Additionally, starting April 12, 2026, all qualifying allergens must be disclosed individually in the Cosmetic Notification Form (CNF) submitted to Health Canada within 10 days of first sale, though exact concentrations remain optional unless the substance is restricted under the Canadian Cosmetic Ingredient Hotlist.

As the beauty industry navigates this transformative regulatory landscape, brands operating in Canada must audit their formulations and update packaging to ensure compliance, marking a new era of transparency in cosmetic ingredient disclosure.